Abstract
On November 9, 2021 in the framework of the XXV Russian Oncology Congress the symposium was held where the various issues of approaches of drug treatment and surgical treatment of metastatic renal cell carcinoma and urothelial cancer were discussed. New drugs are being appeared, large clinical studies are being conducted, new prospects for immunotherapy of malignant neoplasms are being developed, nowadays. One of the new options is immune checkpoint inhibitors. In the framework of the symposium were presented the results of two trials the JAVELIN Renal 101 and the JAVELIN Bladder 100, showing the efficacy and safety of the PD-L1 inhibitor avelumab. The symposium was supported by the alliance between Merck and Pfizer.
Reference33 articles.
1. Злокачественные новообразования в России в 2020 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2021 [Zlokachestvennye novoobrazovaniia v Rossii v 2020 g. (zabolevaemost' i smertnost'). Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow, 2021 (in Russian)].
2. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
3. Choueiri TK, Rini BI, Larkin JMG, et al. Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). 2017 ASCO Annual Meeting I. Abstract TPS4594.
4. Motzer R. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Abstract LBA6_PR (oral presentation).
5. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma